Close Menu

Precision Biosciences

Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs. 

The company plans to sell 7.9 million shares of common stock at $16 per share through its initial public offering.

The company has contracted with EKG Sales Associates for life science lead generation and hired two new sales directors. 

The North Carolina-based firm plans to use the money to continue development of its Arcus genome editing platform.

NEW YORK (GenomeWeb News) – Precision BioSciences and Nova Synthetix today announced a deal for the use of each other's technologies to generate "non-GM," ricin-free castor plants.

NEW YORK (GenomeWeb News) – Precision BioSciences and Agrivida have struck an agreement to use Precision Bio's genetic modification technology to develop traits in corn that can improve animal nutrition for the dairy and beef industries.

NEW YORK (GenomeWeb News) – Precision BioSciences and Cellectis announced Thursday that they have settled patent litigation related to genome engineering technology and have agreed to cross-license certain patents.

NEW YORK (GenomeWeb News) – Precision BioSciences said today that it is suing Lonza Group and a number of its affiliates for patent infringement.

NEW YORK (GenomeWeb News) – Precision BioSciences today claimed victory in a lawsuit filed against the company by Cellectis alleging patent infringement.

NEW YORK (GenomeWeb News) – Illumina disclosed in its quarterly filing with the US Securities and exchange Commission that it paid a total consideration of $95.5 million for its acquisition of BlueGnome in July.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.